Intermountain Medical Center, Murray, Utah; University of Utah, Salt Lake City, Utah, USA.
Am J Cardiol. 2010 Sep 15;106(6):764-9. doi: 10.1016/j.amjcard.2010.04.040. Epub 2010 Aug 1.
Plasma renin activity (PRA) is a measure of renin-angiotensin system activity and is associated with cardiovascular outcomes in patients with heart failure (HF). We conducted a prospective analysis to assess whether elevated baseline PRA is associated with cardiovascular outcomes in 1,165 patients with coronary artery disease (> or =70% stenosis on the coronary angiogram) enrolled in the Intermountain Heart Collaborative Study. The exclusion criteria included previous myocardial infarction (MI) or HF, ejection fraction < or =45%, and a discharge diagnosis of MI/beta-blocker treatment. Baseline PRA measurements were evaluated as risk categories (< or =0.50, 0.51 to 2.30, and >2.30 ng/ml/h) and as tertiles (< or =0.40, 0.41 to 1.90, and > or =1.90 ng/ml/h). Predefined cardiovascular outcomes were assessed for a minimum follow-up of 3 years (mean 6.4 +/- 3.2, maximum 14.6) using Cox regression analysis to adjust for the baseline characteristics. The mean patient age was 64.4 years; most patients were men (73.1%) and hypertensive (63.2%). Elevated baseline PRA (high vs low category; >2.30 vs < or =0.50 ng/ml/h) was associated with a significantly increased risk of 3-year cardiac morbidity/mortality (hazard ratio 1.96; p = 0.004), MI (hazard ratio 2.41; p = 0.02), HF hospitalization (hazard ratio 4.39; p = 0.03), and all-cause death (hazard ratio 1.80; p = 0.01). Elevated baseline PRA was also associated with longer-term HF hospitalization (hazard ratio 2.12; p = 0.004) and all-cause death (hazard ratio 1.56; p = 0.002). Similar results were observed for the PRA tertiles. The association of PRA with outcomes was observed after correction for hypertension, hyperlipidemia, diabetes, a family history of cardiovascular events, smoking, renal failure, and the use of statins. In conclusion, elevated baseline PRA is associated with cardiac morbidity and mortality in patients with coronary artery disease but normal left ventricular function and no previous MI or HF.
血浆肾素活性(PRA)是肾素-血管紧张素系统活性的衡量标准,与心力衰竭(HF)患者的心血管结局相关。我们进行了一项前瞻性分析,以评估 1165 例冠状动脉疾病患者(冠状动脉造影 > 或 =70%狭窄)的基线 PRA 是否升高与心血管结局相关,这些患者均参与了 Intermountain Heart 协作研究。排除标准包括既往心肌梗死(MI)或 HF、射血分数 < 或 =45%以及出院诊断为 MI/β受体阻滞剂治疗。基线 PRA 测量值被评估为风险类别(< 或 =0.50、0.51 至 2.30 和 >2.30ng/ml/h)和三分位组(< 或 =0.40、0.41 至 1.90 和 > 或 =1.90ng/ml/h)。使用 Cox 回归分析在基线特征的基础上进行调整,对至少随访 3 年(平均 6.4+/-3.2,最长 14.6 年)的预定义心血管结局进行评估。患者平均年龄为 64.4 岁;大多数患者为男性(73.1%)和高血压(63.2%)。基线 PRA 升高(高 vs 低类别;>2.30 vs < 或 =0.50ng/ml/h)与 3 年心脏发病率/死亡率(危险比 1.96;p=0.004)、心肌梗死(危险比 2.41;p=0.02)、HF 住院(危险比 4.39;p=0.03)和全因死亡(危险比 1.80;p=0.01)的风险显著增加相关。基线 PRA 升高还与长期 HF 住院(危险比 2.12;p=0.004)和全因死亡(危险比 1.56;p=0.002)相关。PRA 三分位组也观察到类似的结果。在纠正高血压、高血脂、糖尿病、心血管事件家族史、吸烟、肾功能衰竭和他汀类药物使用后,PRA 与结局的相关性仍然存在。总之,在左心室功能正常且无既往 MI 或 HF 的冠状动脉疾病患者中,基线 PRA 升高与心脏发病率和死亡率相关。